Stock page
Coiled Therapeutics PLC (ROQAF)
Coiled Therapeutics PLC is an oncology company engaged in pursuing opportunities to find new therapies for cancer. The product pipeline of the company consists of AO-252, a novel TACC3 inhibitor currently in Phase I clinical trials in the USA; and STAT-6 siRNA programme for immunology indications. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.
Quote snapshot
$0.0964
Daily change: —
ExchangeOTCPK
Updated2026-05-09T04:24:13.425041Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|